Related Experiment Video
Updated: Aug 12, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Maintenance therapy in ulcerative colitis and Crohn's disease
1Mount Sinai School of Medicine, City University of New York, New York, USA.
Journal of Clinical Gastroenterology
|March 1, 1995
Summary
Aminosalicylates effectively maintain remission for ulcerative colitis and Crohn's disease. Oral mesalamine (5-aminosalicylic acid) is particularly useful for preventing Crohn's recurrence after surgery.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, requires long-term management strategies.
- Maintaining remission is crucial for improving patient quality of life and preventing disease progression.
Purpose of the Study:
- To review the efficacy of aminosalicylates in maintaining remission for ulcerative colitis and Crohn's disease.
- To compare the roles of aminosalicylates, corticosteroids, cyclosporine, and antimetabolites in IBD management.
Main Methods:
- Literature review of studies on aminosalicylates, corticosteroids, cyclosporine, and antimetabolites in IBD.
- Analysis of dose-response relationships and specific indications for each drug class.
Main Results:
- Aminosalicylates, including oral mesalamine and rectal 5-aminosalicylic acid, are effective for maintaining IBD remission.
- Oral mesalamine reduces Crohn's disease recurrence post-surgery; efficacy is dose-dependent (>2 g/day).
- Corticosteroids and cyclosporine are better for inducing remission than maintenance; antimetabolites (azathioprine, 6-mercaptopurine) offer safe, long-term steroid-sparing therapy.
Conclusions:
- Aminosalicylates are a cornerstone for maintaining IBD remission.
- Different drug classes have distinct roles in induction versus maintenance therapy for IBD.
- Optimizing drug selection and dosage is key for effective long-term IBD management.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD: